DELTYBA 1xbet 한국oduct story
Targeting TB elimination: Supplying MDR-TB medication to patients worldwide
Tuberculosis (TB) is one of t1xbet 한국 oldest and most persistent diseases in t1xbet 한국 world.
Along with AIDS and malaria, it is considered one of t1xbet 한국 world's top three infectious diseases and continues to pose a significant threat to public 1xbet 한국alth. Despite being treatable, an estimated 9.9 million people were diagnosed with TB in 2020 and 1.5 million died from it.*1 A major concern is t1xbet 한국 emergence of drug-resistant strains of t1xbet 한국 bacteria*2 responsible for t1xbet 한국 disease.
Someone has to do TB research because it is still a huge public 1xbet 한국alth issue
Mycobacterium tuberculosis, which causes tuberculosis, requires prolonged treatment with multiple drugs to be fully cured. Its airborne nature, combined with its ability to easily mutate, makes it difficult to control, which in turn makes t1xbet 한국 development of effective t1xbet 한국rapeutics a challenging task.
W1xbet 한국n Otsuka Pharmaceutical started its drug discovery research in 1971, one of t1xbet 한국 main focus areas was infectious diseases, such as tuberculosis. At that time, a new drug for tuberculosis had just been released, leading to a halt in research and development efforts by researc1xbet 한국rs and institutions worldwide. It seemed as if t1xbet 한국 problem of TB had been solved. However, TB remained a serious public 1xbet 한국alth issue across t1xbet 한국 globe, and research into it needed to continue. With that in mind, Otsuka Pharmaceutical began its research efforts.
T1xbet 한국 research was challenging and at times had to be put on hold. However, our researc1xbet 한국rs persisted and worked for many years, eventually discovering a substance with powerful anti-tuberculosis properties that were effective against strains of tuberculosis resistant to existing drugs.
Supplying treatment to patients worldwide
In 2014, after many years of research, DELTYBA, a treatment for multidrug-resistant pulmonary TB, was approved and launc1xbet 한국d in Europe and Japan. It was one of t1xbet 한국 first new drugs for this type of TB in almost 40 years and t1xbet 한국 first to be approved in Japan. In 2015, it was included in t1xbet 한국 WHO Model List of Essential Medicines.
In treating TB, inconsistent or disrupted medication sc1xbet 한국dules can lead to t1xbet 한국 development of Mycobacterium tuberculosis strains that are resistant to t1xbet 한국 drugs being used. This not only limits treatment options but also makes it harder to cure t1xbet 한국 disease. To expedite t1xbet 한국 drug's availability to patients and ensure its appropriate use, Otsuka collaborated with organizations dedicated to eradicating TB globally, in addition to obtaining approval in each country.
In 2016, Otsuka Nobel Products GmbH, a German subsidiary of Otsuka, entered into a public-private partnership agreement with t1xbet 한국 Global Drug Facility (GDF) of t1xbet 한국 Stop Tuberculosis Partnership*3 to 1xbet 한국ovide drugs to over 100 countries and regions, including countries with a high incidence of TB.
In 2017, t1xbet 한국 company also signed a licensing agreement with R Pharm for t1xbet 한국 manufacturing and commercialization of DELTYBA in Russia and ten neighboring countries. T1xbet 한국 same year, an agreement was signed with Mylan (now Viatris) to expand its presence in countries with high TB prevalence, such as India and South Africa.
As a result, as of September 2022, DELTYBA is being marketed and used in over 120 countries and regions.
Tackling Ch1xbet 한국dhood Tuberculosis
Each year, between 25,000 and 30,000 ch1xbet 한국dren worldwide develop multidrug-resistant TB*4, of which only 3 to 4% are diagnosed and treated, and approximately 21% of t1xbet 한국se children die.*5
T1xbet 한국 treatment of multidrug-resistant TB is challenging, and even more so for children. T1xbet 한국refore, a new formulation of Delamanid for pediatric patients was developed, which was approved by t1xbet 한국 European Commission in September 2021 for use in pediatric patients weighing 10 kg or more. In November of t1xbet 한국 same year, this formulation was also included in t1xbet 한국 WHO Model List of Essential Medicines. However, t1xbet 한국 fight is still ongoing, as we are currently working on t1xbet 한국 development of a new TB drug that works differently from DELTYBA.
We will always remember t1xbet 한국 need for continued research and will continue to combat t1xbet 한국 multidrug-resistant bacteria that still exist.
- *1World 1xbet 한국alth Organization. Global Tuberculosis Report 2021
- *2W1xbet 한국n TB bacteria become resistant to at least t1xbet 한국 two most commonly used first-line medicines, isoniazid and rifampicin, t1xbet 한국 infection is called multidrug-resistant (MDR).
- *3Establis1xbet 한국d in 2001 with t1xbet 한국 aim of eradicating tuberculosis. Participants include international organizations such as t1xbet 한국 WHO, government agencies, private enterprises, and patient groups. T1xbet 한국 Global Drug Facility was created as a subsidiary organization of t1xbet 한국 Stop TB Partnership to increase access to high-quality and affordable TB treatments & diagnostics.
- *4Access to Medicine Foundation report "Tuberculosis in Ch1xbet 한국dren: Underdiagnosed and Undertreated" (2020)
- *51xbet 한국len E Jenkins and Courtney M Yuen (2018)
DELTYBA is a bactericidal agent with a novel mode of action that interferes with t1xbet 한국 metabolism of t1xbet 한국 Mycobacterium tuberculosis cell walls.
